Articles tagged with Cancer Treatments
A new treatment shows promise for people with high-risk smoldering multiple myeloma, delaying cancer progression and improving overall survival. Daratumumab significantly reduces risk of progression to active disease and improves patient outcomes.
The American College of Surgeons Geriatric Surgery Verification program significantly decreases hospital stays among older cancer patients, increasing their independence and likelihood of discharge home. The program addresses the unique needs of older adults undergoing major abdominal oncologic procedures.
Omid Veiseh, a Rice University bioengineer, has been elected as a National Academy of Inventors Fellow for his significant contributions to innovation and society's welfare. He holds over 5,000 issued US patents and has demonstrated leadership in biotechnology.
Experts discuss strategies and best practices for sharing accurate, evidence-based health information with patients and caregivers. The event aimed to empower people with cancer to make informed choices about their care.
A new MRI-based imaging technique can rapidly assess ovarian cancer subtypes and their response to treatment, allowing for personalized treatment planning. The technique, called hyperpolarised carbon-13 imaging, distinguishes between two different subtypes of ovarian cancer and reveals their sensitivities to treatment.
Scientists at UCSF have developed engineered T cells that act as immune referees to soothe overreacting immune responses and mope up inflammatory molecules. These cells could improve treatment for organ transplants, type 1 diabetes and other autoimmune conditions by reducing the need for harsh immunosuppressant drugs.
A study published in Nature reveals that dietary fructose promotes tumor growth in animal models of melanoma, breast cancer, and cervical cancer. The liver converts fructose into usable nutrients for cancer cells, a finding that could lead to new treatment avenues.
A series of five papers highlights critical public health challenges related to cancer control in eight SAARC countries and the Rohingya refugee population in Bangladesh. The studies identify barriers contributing to significant disparities in cancer outcomes and actionable solutions to address these challenges.
Researchers found that immunosuppression in prostate cancer is associated with a specialised epithelial subtype. This interaction between the immune system and club-like epithelial cells can lead to treatment resistance in patients with advanced, treatment-resistant prostate cancer.
The Phase Ib/II FELIX trial demonstrated a 76.6% response rate and 55.3% complete remission rate in 127 evaluable patients treated with obe-cel CAR T cell therapy. The median event-free survival was 11.9 months, and the overall survival was 15.6 months.
The ESMO Asia Congress 2024 will focus on multidisciplinary oncology in the Asian region, featuring novel treatment modalities, management of specific cancer types and pan-Asian trials. Key highlights include insights into genetics, biology and practice differences between West and Asia.
The Gustave Roussy Prize recognizes scientists whose work improves cancer treatment and patient outcomes. Established by Pierre Fabre Laboratories, the €200,000 award aims to push boundaries of oncology and offer personalized treatments.
Insilico Medicine has received FDA clearance for ISM5939, a potential best-in-class oral small molecule inhibitor targeting ENPP1 for the treatment of solid tumors. ISM5939 demonstrated robust anti-tumor efficacy in preclinical studies and showed favorable safety profiles.
A recent analysis reveals significant gaps in cancer drug cost and availability between high- and low-income countries. Inequities in access to therapy, screening, and healthcare infrastructure contribute to higher cancer incidence and mortality rates in low-income countries.
The conference explores molecular determinants of cancer therapy resistance, a major challenge in the fight against cancer. Researchers discuss new therapeutic approaches and address resistance mechanisms involving tumour cells and the tumour microenvironment.
Researchers have created a method to track genetically modified immune cells using PET scans, providing real-time insights into their behavior and persistence in solid tumors. This technology has the potential to inform personalized treatment options and optimize therapy regimens.
The National Comprehensive Cancer Network (NCCN) is collaborating with leading cancer centers in China to improve cancer treatment and outcomes. NCCN Guidelines provide evidence-based recommendations for cancer treatment, prevention, and supportive care, guiding high-quality care globally.
Researchers at Anglia Ruskin University are investigating the complex relationship between fat tissue and colorectal cancer. The study aims to enhance knowledge of the tumour microenvironment, uncover new molecules crucial for cancer growth, and develop more effective treatments.
Researchers developed a new photoacoustic imaging technique that addresses skin tone bias in breast cancer detection. The technique, combined with specific wavelengths and beamforming methods, enhances target visibility across all skin tones, providing clearer images with improved signal-to-noise ratios.
New research shows that routine symptom screening using a validated tool (SSPedi) can reduce symptom burden and support implementing care pathways for improved symptom management. This study found a clinically meaningful decrease in total symptom score, with 12 of 15 symptoms measured showing significant improvement.
A Chinese Medical Journal study reveals that patients with prostate cancer can undergo surgical removal without a pre-operative biopsy, using a combination of mpMRI and PSMA PET/CT imaging. This approach reduces costs and complications associated with traditional biopsy methods.
The new hospital will provide patient-centered care with personalized, compassionate treatment and groundbreaking research. Patients will have access to top specialists and pioneering therapies in cancer treatment.
Continuous Medicaid enrollment is associated with a lower rate of late-stage lymphoma diagnosis, but fewer than half of patients are continuously enrolled before diagnosis. The study found that continuous coverage was strongly linked to a lower likelihood of late-stage diagnosis, especially in young adults.
A recent study found that only half of young cancer patients report discussing fertility preservation options with their healthcare provider. The study, which included 473 patients between the ages of 18 and 49, highlights the need for comprehensive reproductive health care in oncology treatment. Fertility preservation discussions were...
Researchers at UC Riverside develop a novel method to degrade the Pin1 protein, which is involved in pancreatic cancer development. The 'molecular crowbar' strategy has the potential to target and break down harmful proteins, offering new hope for cancer therapy.
AI models trained on limited data may misdiagnose certain populations, particularly those in underserved communities. Researchers propose six key strategies to develop fair AI models, including using diverse datasets and transparent decision-making processes.
A recent study has uncovered a genetic variant in the PSA gene that is associated with aggressive prostate cancer. This finding could lead to the development of a novel point-of-care device that can identify high-risk patients with low blood PSA levels, enabling early detection and treatment.
Researchers developed a new imaging technique using fluorescence-guided surgery to enhance visibility of tumors and nerves during head and neck cancer surgery. The technique uses two near-infrared fluorophores, one for tumors and another for facial nerves, allowing for clear differentiation between cancerous tissues and nerves.
Clinicians should avoid using 'never words' that can scare, offend, or diminish agency in patients and families dealing with serious illness. Researchers recommend alternative language and methods for clinicians to identify their own never words.
The National Comprehensive Cancer Network has updated its guidelines for genetic/familial high-risk assessment, incorporating the latest scientific research and expert recommendations to enhance screening practices and treatment options. The expanded guidelines cover various cancer types and provide guidance on genetic testing, heredit...
A joint research team at Korea University College of Medicine announced the world's first comparative results of single-port robotic thymectomy, showing a lower conversion rate to multi-port surgery and shorter hospital stays. The study demonstrated that single-port robotic thymectomy is a safer alternative to traditional VATS thymectomy.
Researchers analyzed tumor samples from 64 SCLC patients, identifying promising results for biomarkers DLL3 and TTF-1. These biomarkers showed potential as targets for therapies like Tarlatamab and improved survival rates in patients with TTF-1-positive tumors.
Scientists at Johns Hopkins Medicine identified 16 genes that breast cancer cells use to survive in the bloodstream, including MUC1, which is already in clinical trials. The research showed that hypoxic cells are able to migrate to higher oxygen levels and form metastasis in the body, leading to a worse prognosis.
A new study has found that Canadian women who did not identify as White have an earlier peak age of breast cancer diagnosis and higher proportions of cases diagnosed under age 50. They also experience an earlier peak age of death, with a 7-year gap in mortality rates compared to their White counterparts.
International oncology experts have gathered in Accra, Ghana to update cancer treatment recommendations for Sub-Saharan Africa. The NCCN Harmonized Guidelines provide context-appropriate, evidence-based care strategies tailored to the region's unique challenges.
The National Comprehensive Cancer Network has joined forces with the Vietnam National Cancer Hospital to create Harmonized Guidelines for Vietnam, a framework for improving and standardizing cancer care in the country. The guidelines are based on NCCN's Clinical Practice Guidelines in Oncology, with modifications to reflect local needs.
This prospective cohort study found that evidence-based smoking cessation treatment within 6 months of a cancer diagnosis significantly improves survival outcomes. Smoking cessation is an essential early clinical intervention for patients with cancer, supporting the maximization of survival benefits.
The University of Chicago Medical Center will build a state-of-the-art cancer pavilion with a $75 million donation from the AbbVie Foundation. The facility aims to address health inequities in cancer outcomes and provide access to cutting-edge treatments, as part of UChicago Medicine's efforts to advance global cancer care.
A pilot study by NCCN Cancer Center demonstrates the usability of HERC in advancing equitable cancer care delivery, with all participating sites strongly agreeing on its applicability. The tool features 19 practice evaluation and change recommendations to address disparity and bias in care delivery.
Researchers developed HPV16 peptide microspheres to induce specific cytotoxic T lymphocytes, leading to tumor regression in cervical cancer models. The approach combines peptide-based vaccinations with microsphere technology to enhance immune responses and eliminate tumor cells.
A new study found that CAR-T cell therapy success is predicted by three key features: the CD4/CD8 ratio in infusion products, the presence of T-cell exhaustion signals before infusion, and the expansion of T-cells during therapy. These factors can help improve treatment outcomes.
Non-Hispanic Black patients are more likely to receive inadequate care and experience poor survival outcomes due to delays in treatment initiation. Guideline-concordant care is crucial in improving survival rates among these patients.
A new discovery by Cold Spring Harbor Laboratory's Lloyd Trotman suggests that menadione, a precursor to vitamin K, can slow prostate cancer progression in mice. The supplement depletes a lipid called PI(3)P, killing cancer cells and slowing disease progression significantly.
Researchers discovered a gene-mutation pathway that can lead to targeted therapies for blood cancers. The TET2 gene's enzymatic activity regulates chromatin state and leukaemogenesis, providing new therapeutic targets.
The UCLA Urology department has been awarded $6 million to continue the IMPACT program, providing comprehensive prostate cancer treatment for underinsured and uninsured Californians. The program has helped over 2,300 men receive treatment services since its inception.
Researchers from UT Arlington sequenced RNA genes of pythons, discovering conserved pathways in humans that are activated uniquely by these snakes. This knowledge helps explain intestinal regeneration and metabolism changes, offering potential therapeutic targets.
Polyploidy, a state with extra genetic material, allows cancer cells to survive longer under DNA damage. This phenomenon explains why some cancers are resistant to anti-cancer drug treatments.
Researchers at Penn State College of Medicine have re-engineered natural killer immune cells with blue light-activated protein function, allowing them to infiltrate and kill solid tumor spheroids. The technology has shown promising results in killing breast cancer and melanoma cells within seven days.
Researchers at Osaka University demonstrated that ultra-short, high-dose proton irradiation increases cell survival rates even under normoxic conditions. This breakthrough could lead to the development of a cancer treatment method with fewer side effects.
A study analyzing Reddit posts reveals that breast cancer patients struggle with unmet emotional and financial concerns during treatment and long after. The research highlights the importance of providing adequate support and education to address these concerns.
Researchers found that ApoE protects melanoma cells from ferroptosis by increasing antioxidant capacity and neutralizing lipids. This discovery highlights the APOE gene as a critical factor in melanoma cell survival, potentially opening new avenues for treatment.
Researchers developed an AI model that uses machine learning and combination theory to predict suspicious skin lesions. The new C4C Risk Score has an accuracy of 69% and significantly outperformed existing methods, including 7PCL and Williams score.
A groundbreaking study has demonstrated the clinical success of a new nanoparticle-based, laser-guided therapy for prostate cancer treatment. The therapy successfully eliminated cancerous cells in 73% of patients after 12 months while preserving key functions and side effects.
Researchers at Japan Advanced Institute of Science and Technology have developed a novel method to culture antitumor bacteria using porous scaffolds, enhancing their anticancer properties and improving safety in animal testing. The approach resulted in improved survival rates in mice with breast cancer, including drug-resistant cases.
Researchers from IOCB Prague have created new-generation prodrug activators that can enhance the effectiveness of anti-cancer therapies by targeting malignant tumours more precisely. These compounds allow for faster release of drugs in the body, increasing the utilization of administered doses.
Researchers at ChristianaCare Gene Editing Institute use CRISPR tools to safely disable gene mutation linked to treatment-resistant melanoma. The approach targets melanoma tumor cells while leaving healthy cells alone, restoring sensitivity to anticancer drugs.
Researchers have identified a critical genetic group that is near incurable using current therapies, leading to improved survival and quality of life for children with Group 3 medulloblastoma. The study also uncovered a potential targetable mechanism for new therapies aimed at improving outcomes.
A new study found that 5-fluorouracil kills cells by interfering with RNA synthesis, not DNA damage. The findings suggest that combining 5-FU with drugs affecting RNA synthesis could make it more effective in patients with gastrointestinal cancers.
Researchers have discovered a novel immunotherapy approach using natural killer T cells to combat solid tumors. By targeting tumor-associated macrophages and promoting systemic immune responses, CAR-natural killer T cells demonstrate superior antitumor activity compared to traditional CAR-T therapy.
Researchers at Michigan Medicine have discovered a new subtype of aggressive prostate cancer and identified a potential degrader to target it. The study found that a genetic alteration in the CDK12 gene drives cancer development, and a degrader targeting this gene shows promise in destroying cancer cells.